Diagonal Bio
Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market
The granting of the delisting application is conditioned by Diagonal Bio fulfilling the formal listing requirements of NGM and thus, that the securities in Diagonal Bio are admitted to trading on NGM.
Shareholders in Diagonal Bio will not need to take any action in connection with the change of marketplace.
For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO
Phone: +46 70 305 24 88
E-mail: kw@diagonalbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se
About Diagonal Bio
Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.
| Datum | 2025-03-04, kl 16:44 |
| Källa | Cision |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.